Cozad Asset Management Inc. acquired a new stake in Amgen, Inc. (NASDAQ:AMGN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 1,552 shares of the medical research company’s stock, valued at approximately $286,000.

Several other institutional investors also recently added to or reduced their stakes in the company. LSV Asset Management raised its stake in shares of Amgen by 3.2% during the second quarter. LSV Asset Management now owns 4,157,649 shares of the medical research company’s stock worth $767,460,000 after purchasing an additional 128,865 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Amgen by 2.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 3,207,242 shares of the medical research company’s stock worth $592,025,000 after purchasing an additional 72,205 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Amgen by 17.0% during the second quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock worth $436,551,000 after purchasing an additional 343,690 shares during the last quarter. Aristotle Capital Management LLC raised its stake in shares of Amgen by 3.9% during the first quarter. Aristotle Capital Management LLC now owns 2,279,468 shares of the medical research company’s stock worth $388,604,000 after purchasing an additional 86,378 shares during the last quarter. Finally, Swiss National Bank raised its stake in shares of Amgen by 3.2% during the second quarter. Swiss National Bank now owns 2,227,926 shares of the medical research company’s stock worth $411,253,000 after purchasing an additional 69,500 shares during the last quarter. Institutional investors and hedge funds own 82.44% of the company’s stock.

NASDAQ:AMGN opened at $200.81 on Tuesday. The firm has a market capitalization of $129.83 billion, a price-to-earnings ratio of 14.90, a price-to-earnings-growth ratio of 1.96 and a beta of 1.40. The company has a debt-to-equity ratio of 2.03, a current ratio of 3.39 and a quick ratio of 3.12. Amgen, Inc. has a 1 year low of $163.31 and a 1 year high of $204.42.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, July 26th. The medical research company reported $3.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.52 by $0.31. The firm had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $5.73 billion. Amgen had a return on equity of 43.18% and a net margin of 10.19%. Amgen’s revenue was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.27 earnings per share. sell-side analysts anticipate that Amgen, Inc. will post 13.95 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 7th. Shareholders of record on Friday, August 17th were issued a $1.32 dividend. This represents a $5.28 annualized dividend and a yield of 2.63%. The ex-dividend date of this dividend was Thursday, August 16th. Amgen’s dividend payout ratio (DPR) is 41.97%.

Several research firms have recently commented on AMGN. Jefferies Financial Group restated a “buy” rating and set a $220.00 price target on shares of Amgen in a research note on Friday, August 24th. Leerink Swann set a $209.00 price target on Amgen and gave the stock a “hold” rating in a research note on Monday. TheStreet upgraded Amgen from a “c+” rating to a “b-” rating in a research note on Friday, May 25th. Citigroup upped their price target on Amgen from $188.00 to $200.00 and gave the stock a “neutral” rating in a research note on Monday, July 30th. Finally, Piper Jaffray Companies upped their price target on Amgen from $190.00 to $210.00 and gave the stock an “overweight” rating in a research note on Thursday, July 26th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $203.03.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction on Monday, July 16th. The stock was sold at an average price of $195.71, for a total value of $298,457.75. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.27% of the stock is currently owned by corporate insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Recommended Story: Dow Jones Industrial Average (DJIA)

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.